Objective: To determine whether and to what extent vitamin D deficiency is associated with multiple sclerosis (MS) risk.
While there is much evidence supporting a role for adequate vitamin D nutrition in reducing multiple sclerosis (MS) risk, 1 there are currently only 2 prospective studies examining whether 25-hydroxyvitamin D (25[OH]D) levels in healthy individuals predict future MS risk. 2, 3 While both studies found that elevated levels of 25(OH)D (either $75 nmol/L 3 or $100 nmol/L 2 ) among healthy young adults were associated with a ;60% decreased risk of later developing MS, both studies included fewer than 200 non-Hispanic Caucasian patients with MS, and one was not able to directly examine whether levels of insufficient or deficient 25(OH)D were associated with an increased risk of MS as only 5% of individuals had 25(OH)D levels below 50 nmol/L, 2 and the other reported no associations with 25(OH)D lower than 75 nmol/L. 3 Therefore, we sought to examine the association between 25(OH)D and MS risk in a large cohort of Finnish women, a population with historically low 25(OH)D levels, 4 and specifically examine whether deficient 25(OH)D levels are associated with an increased MS risk.
METHODS Study population. The Finnish Maternity Cohort (FMC) began in 1983 and comprises over 800,000 women who gave a blood sample for routine prenatal testing. The majority of blood samples were collected between approximately 10-14 weeks 6 For the remaining 640 women, medical records were not available, but the Kela registry listed them as having received disease-modifying therapy for MS. The date of MS diagnosis was set as the earliest diagnosis date recorded in HILMO, Kela, or the medical records. Date of MS onset was only available for the cases confirmed via medical record review and this date was used as the index date to identify serum samples in the FMC collected prior to onset. For Kela-confirmed cases, the date of diagnosis was used.
Each patient with MS was matched to up to 3 controls on birth date (62 years) and area of residence (postal code: ,10000, 10000 to ,30000, 30000 to ,50000, 50000 to 91000, .91000). At least 1, and up to 3, serum samples were available from pregnancies occurring prior to MS diagnosis. There were a total of 6,200 serum samples available from 1,092 cases and 2,123 controls. Two or more serum samples were available from 511 cases and 831 matched controls.
25(OH)D measurement. Serum 25(OH)D levels were mea-
sured in all prediagnostic case and control samples using a chemiluminescence microparticle immunoassay and an Architect i2000SR automatic analyzer (Abbott Diagnostics, Abbott Park, IL). The overall assay coefficient of variation calculated from duplicate samples with repeated measures of 25(OH)D was 2.5%. The serum samples were assayed in 2 batches (n 5 3,354 4 total gravidity (1, 2, $3), and parity (0, 1, $2). The missing indicator method was used to model gravidity and parity for women missing information on these covariates in order to retain all observations in the analyses. Tests for linear trends across the a priori defined categories and quintiles were conducted by assigning the median 25(OH)D value for each category/quintile to all cases/ controls in that category and modeling the median 25(OH)D as a linear variable. In sensitivity analyses, we restricted to MS cases with clinical confirmation (via medical record review) of MS (n 5 604) and to MS cases with more than one 25(OH)D measurement from multiple pregnancies prior to diagnosis (n 5 511) and their matched controls (figure 1). To evaluate whether the associations between 25(OH)D and MS varied by season, samples were categorized by month of collection into months of high ultraviolet (UV) light (May through October, n 5 800 cases/1,740 controls) or low UV light (November through April, n 5 764 cases/1,677 controls). Women with samples collected in both high and low UV months will be in both analyses and we averaged 25(OH)D levels for women with more than one sample collected within the high or the low UV month period. Unconditional logistic regression adjusting for the age and geographic location, as well as the other factors listed above, was used to estimate relative risks (RRs) and 95% CIs associated with 50 nmol/L increases in 25(OH)D in the UV-specific analysis.
RESULTS 25(OH)D levels exhibited the expected seasonal distribution ( figure 2A ), but the yearly 25(OH)D averages were remarkably stable between 1983 and 2004, the year when Finland formally recommended pregnant women take vitamin D supplements ( figure 2B) .
Women who developed MS had average prediagnostic serum 25(OH)D levels 1.3 nmol/L lower than controls; over half of patients and controls had deficient levels of 25(OH)D (,30 nmol/ L), and over one-third of patients and controls had insufficient levels (30 to ,50 nmol/L) (table). Only 6 patients and 9 controls had 25(OH)D levels $75 nmol/L, and of these, only 1 patient and 2 controls had levels $100 nmol/L. Among the 604 patients with MS with medical record confirmation, there was an average of 9.5 years between first sample collection and recorded date of MS diagnosis.
In multivariate-adjusted analyses including all cases and controls, a 50 nmol/L increase in 25(OH) D was associated with a 39% reduced risk of MS conducted in the United States among 148 nonHispanic white patients with MS and 296 controls in the US military, 2 and the other among 192 patients and 384 controls residing in northern Sweden. 3 In both studies, elevated levels of 25(OH)D (above 75 or 100 nmol/L) were associated with a 60% reduced risk of MS. However, neither study reported the effects of vitamin D insufficiency or deficiency. In the US study, too few individuals had insufficient or deficient 25(OH)D levels (only 5% ,50 nmol/L) to directly assess this question (average 25[OH]D in non-Hispanic white participants was 75 nmol/L), 2 and in the Swedish study, 3 while overall mean 25(OH)D levels were lower (40 nmol/L), investigators reported not finding any associations between 25(OH)D levels and other "predefined 25(OH)D strata," but they did not report specific findings.
Our findings suggest that correcting vitamin D deficiency among reproductive age women may reduce their future risk of developing MS. In a previous study in this cohort, 7 we found that maternal vitamin D deficiency during pregnancy was associated with about a 2-fold increased risk of MS in the offspring, and a Danish study 8 found low neonatal 25(OH)D levels were associated with an increased MS risk in adulthood, suggesting that correcting maternal vitamin D deficiency during pregnancy may also reduce the risk of MS in the offspring. What is less clear, however, is what, if any, specific recommendation with regards to timing of vitamin D supplementation can be made. It is possible that individuals with sufficient levels ($50 nmol/L) of 25(OH)D had behavior practices, such as regularly using supplements, that they or their children followed for many years. More research on the benefits of timing and optimal dose of vitamin D supplementation on MS risk are needed, but striving to achieve vitamin D sufficiency over the life course will likely have multiple health benefits.
Strengths of our study include a large, nested casecontrol sample, with over 1,000 patients with MS and 2,000 controls, drawn from a well-defined population-based cohort of Finnish women, and the utilization of the national HILMO and Kela registries to identify MS cases, an approach that minimizes selection bias. Further, serum samples were collected on average 9.3 years prior to the MS diagnosis, reducing reverse causation as an explanation of our results. Serum samples were collected from the majority of mothers during the first trimester of pregnancy at ;10-14 weeks gestation. While vitamin D metabolism changes to meet the vitamin D and calcium needs of both the mother and fetus, 9 longitudinal studies of 25(OH)D in pregnant women and comparisons of 25(OH)D in pregnant and nonpregnant women suggest that 25(OH)D levels during the first trimester are reflective of nonpregnancy 25(OH)D levels. 4, 10 Some limitations of this study to consider include the inability to adjust for other MS risk factors such as body mass index in early life, EpsteinBarr virus infection, smoking, and human leukocyte antigen status, but previous work suggests these are probably not major confounders of the vitamin D-MS association. [11] [12] [13] Further, the majority of the women in the FMC are Caucasian, and as such, our results may not be generalizable to women of other race groups. We do not have specific information on individual race/ethnicity and other demographic variables such as education level were not available. Previous findings of a decreased MS risk with increasing 25(OH)D levels has held for both men and women, 2,3 so vitamin D deficiency may also increase risk of MS in men, but this requires separate study. Finally, it should be noted that although the assay that we used to assess serum 25(OH)D levels is highly reliable, and thus the ranking of women according to their vitamin D status is likely accurate, there are variations in absolute 25(OH)D levels across methods and within methods across different laboratories. 14 These potential variations should be considered when comparing absolute 25(OH)D levels across different studies.
Our results further support and extend those of previous prospective studies of 25(OH)D levels in young adults and risk of MS, and suggests that many individuals are exposed to an increased MS risk that could be reduced by broad population-based programs to prevent vitamin D deficiency.
